Maria Gabriela Gomes de Lima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Gabriela Gomes de Lima has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Chitra Hosing
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
2 shared publications - Igor Daniel Alves Ribeiro
Departamento de Biologia Molecular e Biotecnologia, Instituto de Biociências and Programa de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, RS, 91500-970, Brazil; Departamento de Genética and Programa de Pós-Graduação em Genética e Biologia Molecular, Instituto de Biociências, Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, RS, 91500-970, Brazil
2 shared publications - Issa F. Khouri
Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas USA
2 shared publications - Júlia Karoline Ferreira Moura
Universidade Federal de Sergipe - UFS
2 shared publications - Luciane Maria Pereira Passaglia
Universidade Federal do Rio Grande do Sul, Brazil
2 shared publications - Marcos Cabral de Vasconcellos Barretto
Universidade Federal de Sergipe, Departamento de Engenharia Agronômica, Laboratório de Remediação de solos. SE, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Pesquisa Agropecuária Brasileira
- Vol. 60, e04040
Antagonistic potential of endophytic bacteria from tomato seedlings
The objective of this work was to evaluate the antagonistic potential of endophytic bacteria isolated from 'Cereja Vermelho', 'Rasteiro Rio Grande', and 'Chapolin' tomato seedlings against the ALT23 Alternaria sp. fungus. Of the 23 endophytic isolates obtained, 12 were selected due to their greater effect on the mycelial growth of ALT23. Antagonism was tested in a completely randomized design, with 13 treatments (ALT23 and 12 isolates), with four replicates. The selected endophytic bacteria inhibited from 29.8 to 64.2% of the mycelial diameter and from 33.7 to 72.4% of the growth rate of ALT23.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Pesquisa Agropecuária Brasileira
- Vol. 60, e04040
Open AccessAntagonistic potential of endophytic bacteria from tomato seedlings
The objective of this work was to evaluate the antagonistic potential of endophytic bacteria isolated from 'Cereja Vermelho', 'Rasteiro Rio Grande', and 'Chapolin' tomato seedlings against the ALT23 Alternaria sp. fungus. Of the 23 endophytic isolates obtained, 12 were selected due to their greater effect on the mycelial growth of ALT23. Antagonism was tested in a completely randomized design, with 13 treatments (ALT23 and 12 isolates), with four replicates. The selected endophytic bacteria inhibited from 29.8 to 64.2% of the mycelial diameter and from 33.7 to 72.4% of the growth rate of ALT23.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Ciência E Agrotecnologia
- Vol. 48, e016224
Endophytic bacteria from lettuce seedlings antagonistic to the phytopathogenic fungus Alternaria sp.
Endophytic microorganisms in lettuce plants have received little attention for their potential biological control of phytopathogens. This study aimed to isolate, identify, and select endophytic bacteria from lettuce seedlings cv. Brava and Creta, antagonistic to the phytopathogenic fungus Alternaria sp. (ALT23) in culture media through direct interaction. The experimental design was completely randomized in an 11 x 2 factorial scheme, with 11 treatments [Control - ALT23 and 10 previously selected bacterial isolates] and two evaluation periods (the 5th and 8th day after inoculation) with four replications each. The 16S rDNA gene sequences of the isolates revealed a high similarity with Bacillus tequilensis KCTC 13622, B. subtilis NCIB 3610, B. velezenzis CR-502, B. siamensis KCTC 13613, and Paenibacillus polymyxa ATCC 842. The selected bacterial isolates reduced ALT23 mycelial diameter (46.2-65.3%) and rate (51.8-91.6%). We conclude that endophytic bacterial isolates with antagonistic potential against phytopathogens must be selected after more than five days of cultivation in a culture medium, as longer cultivation times favor endophyte inhibitory activity.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Ciência E Agrotecnologia
- Vol. 48, e016224
Open AccessEndophytic bacteria from lettuce seedlings antagonistic to the phytopathogenic fungus Alternaria sp.
Endophytic microorganisms in lettuce plants have received little attention for their potential biological control of phytopathogens. This study aimed to isolate, identify, and select endophytic bacteria from lettuce seedlings cv. Brava and Creta, antagonistic to the phytopathogenic fungus Alternaria sp. (ALT23) in culture media through direct interaction. The experimental design was completely randomized in an 11 x 2 factorial scheme, with 11 treatments [Control - ALT23 and 10 previously selected bacterial isolates] and two evaluation periods (the 5th and 8th day after inoculation) with four replications each. The 16S rDNA gene sequences of the isolates revealed a high similarity with Bacillus tequilensis KCTC 13622, B. subtilis NCIB 3610, B. velezenzis CR-502, B. siamensis KCTC 13613, and Paenibacillus polymyxa ATCC 842. The selected bacterial isolates reduced ALT23 mycelial diameter (46.2-65.3%) and rate (51.8-91.6%). We conclude that endophytic bacterial isolates with antagonistic potential against phytopathogens must be selected after more than five days of cultivation in a culture medium, as longer cultivation times favor endophyte inhibitory activity.
- 9 December 2009
- Published by Springer Nature in International Journal of Hematology
- Vol. 90 (5) , 627-634
Interleukin-2 and granulocyte–macrophage–colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
Immunomodulation with cytokines was used to improve the result of high-dose chemotherapy (HDC)/autologous hematopoietic stem cell transplantation (AHST). We examined the use of IL-2 and growth factors for mobilization, ex vivo activation of peripheral blood stem cell (PBSC) and maintenance therapy after HDC/AHST in metastatic breast cancer. Eligible patients with metastatic breast cancer for HDC/AHST were assigned to 1 of 3 protocols for PBSC mobilization: G-CSF (group 1); IL-2 + G-CSF (group 2); or IL-2 + G-CSF + GM–CSF (group 3). HDC with cyclophosphamide, carmustine and thiotepa was given from day −7 to −5. PBSCs were treated ex vivo with IL-2 for 24 h and reinfused on day 0. Maintenance therapy included low-dose IL-2, followed by 2 courses of intermediate-dose IL-2. GM–CSF was given from day 1 until neutrophil recovery. Thirty-four patients (10 in group 1, 14 in group 2, and 10 in group 3) were included. Comparable numbers of CD34+ cells were collected from all 3 groups; incremental increases of CD3+ cells were collected from groups 1 to 2 and to 3 (p = 0.03). Major adverse effects from IL-2 were fever, hypotension and fatigue; no treatment-related mortality was seen. At a median follow-up of 790.5 days (range 150–2,722 days), median progression-free survival was 434 days and median overall survival was 1,432 days. Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates.
- 9 December 2009
- Published by Springer Nature in International Journal of Hematology
- Vol. 90 (5) , 627-634
Interleukin-2 and granulocyte–macrophage–colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
Immunomodulation with cytokines was used to improve the result of high-dose chemotherapy (HDC)/autologous hematopoietic stem cell transplantation (AHST). We examined the use of IL-2 and growth factors for mobilization, ex vivo activation of peripheral blood stem cell (PBSC) and maintenance therapy after HDC/AHST in metastatic breast cancer. Eligible patients with metastatic breast cancer for HDC/AHST were assigned to 1 of 3 protocols for PBSC mobilization: G-CSF (group 1); IL-2 + G-CSF (group 2); or IL-2 + G-CSF + GM–CSF (group 3). HDC with cyclophosphamide, carmustine and thiotepa was given from day −7 to −5. PBSCs were treated ex vivo with IL-2 for 24 h and reinfused on day 0. Maintenance therapy included low-dose IL-2, followed by 2 courses of intermediate-dose IL-2. GM–CSF was given from day 1 until neutrophil recovery. Thirty-four patients (10 in group 1, 14 in group 2, and 10 in group 3) were included. Comparable numbers of CD34+ cells were collected from all 3 groups; incremental increases of CD3+ cells were collected from groups 1 to 2 and to 3 (p = 0.03). Major adverse effects from IL-2 were fever, hypotension and fatigue; no treatment-related mortality was seen. At a median follow-up of 790.5 days (range 150–2,722 days), median progression-free survival was 434 days and median overall survival was 1,432 days. Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates.
- Open Access
- 20 November 2009
- Published by American Society of Hematology in Blood
- Vol. 114 (22) , 2310
Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
Abstract 2310 Poster Board II-287
- 20 November 2009
- Published by American Society of Hematology in Blood
- Vol. 114 (22) , 2310
Open AccessAutologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
Abstract 2310 Poster Board II-287